What is Oramed Pharmaceuticals's market cap?

Oramed Pharmaceuticals (ORMP) has a market capitalization of $170.3M and trades on NASDAQ.

Who are Oramed Pharmaceuticals's competitors?

Oramed Pharmaceuticals's key competitors include Eli Lilly and Company, Rani Therapeutics Holdings, Inc. Class A Common Stock, Olema Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Oramed Pharmaceuticals partner with?

Oramed Pharmaceuticals's notable partners include Hefei Tianhui Biotech Co., Ltd., Scilex Holding Company, BioXcel Therapeutics, Inc., and others.

What subsidiaries does Oramed Pharmaceuticals have?

Oramed Pharmaceuticals's subsidiaries include Oramed Ltd., RoyaltyVest Ltd..

Where is Oramed Pharmaceuticals headquartered?

Oramed Pharmaceuticals is headquartered in United States of America and employs approximately 15 people. It has been publicly traded since 2004.

Oramed Pharmaceuticals

ORMP

Market cap

$170.25M+95.7%

Table of contents

Earnings

Q1 2026 report

May 19, 2026

EPS-$0.16

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

EPS estimate$0.43

Competitors

By market cap

Eli Lilly$1.07T+47.2%

Insulet$11.4B-44.4%

Oric Pharmaceuticals, Inc.$1.2B+30.6%

Olema Pharmaceuticals, Inc.$1.0B+217%

Opko Health$936.3M-12.5%

Palisade Bio, Inc.$352.8M+5,595%

Oramed Pharmaceuticals$170.3M+88.6%

Rani Therapeutics Holdings, Inc.$91.0M+279%

By revenue growth

Eli Lilly+47.4%

Insulet+31.9%

Opko Health-11.5%

By net margin

Eli Lilly34.99%+12.3pp

Insulet10.44%-7.9pp

Opko Health-12.4%+14.3pp

Profile

Oramed Pharmaceuticals is a biotechnology company focused on developing innovative oral delivery solutions for therapeutic proteins through its proprietary Protein Oral Delivery (POD) technology platform. The company's primary candidate is an oral insulin capsule designed to withstand the gastrointestinal environment and deliver insulin physiologically via the portal vein. Beyond its core R&D activities, the company operates a strategic investment arm that allocates capital to healthcare, life sciences, and real estate assets to enhance shareholder value.

Competitive position

Oramed is a pioneer in oral protein delivery seeking to disrupt the insulin market, though it currently faces significant competition from established GLP-1 therapies and traditional insulin delivery methods.

GeographiesUnited States, Israel, China

Customer segmentsPatients, Biotech companies, Real estate markets

Business modelR&D, Licensing, Investment, Royalty

SuppliersContract Research Organizations (CROs), Academic research institutions, Raw material suppliers for protein formulations, Clinical trial sites

CustomersPharmaceutical licensing partners, Healthcare systems, End-user diabetic patients

CountryUnited States of America

Listed2004

Employees15.0

CEONadav Kidron

SectorHealthcare

IndustryBiotechnology

Websiteoramed.com

FilingsSEC EDGAR

Questions, answered.

What is Oramed Pharmaceuticals's market cap?: Oramed Pharmaceuticals (ORMP) has a market capitalization of $170.3M and trades on NASDAQ.
Who are Oramed Pharmaceuticals's competitors?: Oramed Pharmaceuticals's key competitors include Eli Lilly and Company, Rani Therapeutics Holdings, Inc. Class A Common Stock, Olema Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Oramed Pharmaceuticals partner with?: Oramed Pharmaceuticals's notable partners include Hefei Tianhui Biotech Co., Ltd., Scilex Holding Company, BioXcel Therapeutics, Inc., and others.
What subsidiaries does Oramed Pharmaceuticals have?: Oramed Pharmaceuticals's subsidiaries include Oramed Ltd., RoyaltyVest Ltd..
Where is Oramed Pharmaceuticals headquartered?: Oramed Pharmaceuticals is headquartered in United States of America and employs approximately 15 people. It has been publicly traded since 2004.